• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ofatumumab vs. teriflunomide for multiple sclerosis

byConstance Wu
August 18, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple sclerosis compared to those treated with teriflunomide

2. The ofatumumab treatment group had less disability worsening, improved number of enhancing lesions per MRI scans, and lower serum neurofilament light chains levels. However, no differences in brain volume was found

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ofatumumab is a CD-20 antibody that selectively depletes B cells while teriflunomide targets both the B and T-cell populations. This trial aimed to evaluate the efficacy and safety of injectable ofatumumab compared to oral teriflunomide in patients with multiple sclerosis. It was determined that treatment with ofatumumab reduced the annualized relapse rate compared to teriflunomide. Ofatumumab treatment was also associated with improved secondary endpoints such as less Expanded Disability Status Scale score regressions at 3 and 6 months but no significant improvement events were shown. MRI detected lesions and serum neurofilament light chain levels were improved in the ofatumumab group compared to the teriflunomide group. The main safety profile difference was an increased incidence of injection-related reactions in the ofatumumab group. This study was limited by the follow-up time as long term adverse events such as the development of neoplasms and mortality differences were not adequately assessed. Taken together, this study demonstrated that ofatumumab is a superior alternative to oral teriflunomide in the treatment of multiple sclerosis with some minor increases in the incidence of injected related reactions.

Click to read the study in NEJM

Relevant Reading: CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date

In-Depth [randomized controlled trial]: This was a 1.6 year, double-blind, double-dummy phase 3 trial with two identical trials with a total of 946 patients with multiple sclerosis with a relapsing-remitting course or a secondary progressive course. Ages of patients ranged from 18 to 55 years. Patients were randomly assigned 1:1 to receive ofatumumab or oral teriflunomide with appropriate placebos. The primary efficacy endpoint demonstrated that ofatumumab improved the adjusted annualized relapse rate (-0.11 [95% CI -0.16 to -0.06], p <0.001) in trial 1 and trial 2 (-0.15 [95% CI -0.20 to -0.09], p <0.001). Secondary endpoints showed less disability worsening events at 3 months (HR 0.66 [95% CI 0.50 to 0.86]), at 6 months (HR 0.68 [95% cI 0.50 to 0.92]) but no improvements at 6 months (HR 1.35 [95% CI 0.95 to 1.92]) in the ofatumamab group. Furthermore, MRI detected lesions and serum neurofilament light chain concentrations were significantly lower on ofatumumab compared to teriflunomide. Brain volume change was not significantly different between groups. Serious adverse events were reported in 9% of ofatumumab patients and 8% of teriflunomide patients. Injection-related systemic reactions were reported in 20% of ofatumumab patients and 15% of placebo injections while injection-site reactions occurred in 11% and 6% respectively.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 1

The Scan by 2 Minute Medicine®: The Last Dance, Head of State, Trouble on the Farm and the Heart of COVID-19!

Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple sclerosisofatumumab
Previous Post

Bariatric surgery improves blood pressure control

Next Post

Reduced physical activity from COVID-19 related restrictions may be linked to higher stress and anxiety levels

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 1

November 22, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Last Dance, Head of State, Trouble on the Farm and the Heart of COVID-19!

November 1, 2022
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis

August 26, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

June 29, 2022
Next Post
Use of legal performance enhancing substances increases risk of future anabolic steroid use

Reduced physical activity from COVID-19 related restrictions may be linked to higher stress and anxiety levels

#VisualAbstract: Afabicin is non-inferior to vancomycin and linezolid for staphylococcal skin and soft tissue infections

#VisualAbstract: Afabicin is non-inferior to vancomycin and linezolid for staphylococcal skin and soft tissue infections

RTS,SA/S01 anti-malarial vaccine efficacy wanes significantly over time

Dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options